{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T06:27:39Z","timestamp":1792218459188,"version":"4.4.0"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2023,1,17]],"date-time":"2023-01-17T00:00:00Z","timestamp":1673913600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,5,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Tyrosine kinase inhibitors remain a cornerstone in managing metastatic clear cell renal cell carcinoma (RCC). The 4 weeks on\/2 weeks off intermittent sunitinib schedule could result in rebound angiogenesis and tumor progression in the 2-week rest period. We propose using bevacizumab during this period for continuous antiangiogenic effects.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Method<\/jats:title>\n                  <jats:p>This was a phase I\/II study of patients with advanced clear cell RCC. Sunitinib was given 50 mg daily on a 4-week on\/2-week off schedule. Bevacizumab was given on day 29 of each sunitinib cycle. The bevacizumab starting dose was 5 mg\/kg, and the dose was escalated to 10 mg if there was no dose-limiting toxicity. The primary endpoints were response rate and progression-free survival (PFS).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Twenty-five patients were recruited. The study was closed prematurely because of poor accrual. No dose-limiting toxicity was observed with 5 mg bevacizumab. One patient achieved a complete response, and 12 achieved a partial response (52% response rate). At a median follow-up of 42.2 months (95%, confidence interval (CI) 32.9 to 51.4), the median PFS duration was 16.5 months (95% CI 4.1-28.8), and the median overall survival time was 33.3 months (95% CI 19.4-47.3). Twenty-two patients (88%) had at least one grade 3 or 4 toxicity; the most common were thrombocytopenia (32%), lymphopenia (32%), hypertension (28%), and fatigue (24%).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Continuous angiogenesis blockade by adding bevacizumab to the sunitinib on\/off regimen for advanced RCC yields significant antitumor activity with manageable increased toxicity.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyac261","type":"journal-article","created":{"date-parts":[[2023,1,17]],"date-time":"2023-01-17T22:42:37Z","timestamp":1673995357000},"page":"e254-e262","source":"Crossref","is-referenced-by-count":9,"title":["Combining Sunitinib and Bevacizumab for the Management of Advanced Renal Cell Carcinoma: A Phase I\/II Trial"],"prefix":"10.1093","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8913-8158","authenticated-orcid":false,"given":"Shouki","family":"Bazarbashi","sequence":"first","affiliation":[{"name":"Medical Oncology, Oncology Center, King Faisal Specialist Hospital and Research Centre , Riyadh , Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Alzahrani","sequence":"additional","affiliation":[{"name":"Medical Oncology, Oncology Center, King Faisal Specialist Hospital and Research Centre , Riyadh , Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Aljubran","sequence":"additional","affiliation":[{"name":"Medical Oncology, Oncology Center, King Faisal Specialist Hospital and Research Centre , Riyadh , Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Elshenawy","sequence":"additional","affiliation":[{"name":"Medical Oncology, Oncology Center, King Faisal Specialist Hospital and Research Centre , Riyadh , Saudi Arabia"},{"name":"Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Menoufia University , Shebin El Kom , Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Mostafa","family":"Gad","sequence":"additional","affiliation":[{"name":"Medical Oncology, Oncology Center, King Faisal Specialist Hospital and Research Centre , Riyadh , Saudi Arabia"},{"name":"Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Ain Shams University , Cairo , Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Maraiki","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, King Faisal Specialist Hospital and Research Centre , Riyadh , Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noura","family":"Alzannan","sequence":"additional","affiliation":[{"name":"Research Unit, Oncology Center, King Faisal Specialist Hospital and Research Centre , Riyadh , Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tusneem","family":"Elhassan","sequence":"additional","affiliation":[{"name":"Research Unit, Oncology Center, King Faisal Specialist Hospital and Research Centre , Riyadh , Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Badran","sequence":"additional","affiliation":[{"name":"Medical Oncology, Oncology Center, King Faisal Specialist Hospital and Research Centre , Riyadh , Saudi Arabia"},{"name":"Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Ain Shams University , Cairo , Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,1,17]]},"reference":[{"issue":"2","key":"2023050815233812000_CIT0001","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"issue":"8","key":"2023050815233812000_CIT0002","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib versus sunitinib in metastatic renal-cell carcinoma","volume":"369","author":"Motzer","year":"2013","journal-title":"N Engl J Med"},{"issue":"6","key":"2023050815233812000_CIT0003","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.ejca.2012.12.010","article-title":"A randomised, double-blind phase III study of pazopanib in patients with advanced and\/or metastatic renal cell carcinoma: final overall survival results and safety update","volume":"49","author":"Sternberg","year":"2013","journal-title":"Eur J Cancer"},{"issue":"5","key":"2023050815233812000_CIT0004","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1136\/jcp.2003.012963","article-title":"Expression of vascular endothelial growth factor, hypoxia inducible factor 1alpha, and carbonic anhydrase IX in human tumours","volume":"57","author":"Jubb","year":"2004","journal-title":"J Clin Pathol"},{"issue":"8","key":"2023050815233812000_CIT0005","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1200\/JCO.2008.19.3342","article-title":"Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma","volume":"27","author":"Escudier","year":"2009","journal-title":"J Clin Oncol"},{"issue":"13","key":"2023050815233812000_CIT0006","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1200\/JCO.2009.26.7849","article-title":"Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival","volume":"28","author":"Escudier","year":"2010","journal-title":"J Clin Oncol"},{"issue":"13","key":"2023050815233812000_CIT0007","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1200\/JCO.2009.26.5561","article-title":"Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206","volume":"28","author":"Rini","year":"2010","journal-title":"J Clin Oncol"},{"issue":"22","key":"2023050815233812000_CIT0008","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N Engl J Med"},{"issue":"18","key":"2023050815233812000_CIT0009","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1002\/cncr.25219","article-title":"Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors","volume":"116","author":"Motzer","year":"2010","journal-title":"Cancer"},{"issue":"4","key":"2023050815233812000_CIT0010","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.eururo.2011.06.017","article-title":"ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease","volume":"60","author":"Patard","year":"2011","journal-title":"Eur Urol"},{"issue":"6","key":"2023050815233812000_CIT0011","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s00280-016-3033-7","article-title":"Phase I study of safety and tolerability of sunitinib in combination with sirolimus in patients with refractory solid malignancies and determination of VEGF (VEGF-A) and soluble VEGF-R2 (sVEGFR2) in plasma","volume":"77","author":"Li","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"issue":"9","key":"2023050815233812000_CIT0012","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med."},{"issue":"14","key":"2023050815233812000_CIT0013","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"issue":"12","key":"2023050815233812000_CIT0014","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med."},{"issue":"14","key":"2023050815233812000_CIT0015","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N Engl J Med. 04 08"},{"key":"2023050815233812000_CIT0016","author":"Robert","year":"2022"},{"key":"2023050815233812000_CIT0017","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1479-5876-5-32","article-title":"Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins","volume":"5","author":"Deprimo","year":"2007","journal-title":"J Transl Med"},{"issue":"9","key":"2023050815233812000_CIT0018","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1200\/JCO.2008.19.0108","article-title":"Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma","volume":"27","author":"Feldman","year":"2009","journal-title":"J Clin Oncol"},{"issue":"19","key":"2023050815233812000_CIT0019","doi-asserted-by":"crossref","first-page":"6277","DOI":"10.1158\/1078-0432.CCR-09-0717","article-title":"A phase I study of sunitinib plus bevacizumab in advanced solid tumors","volume":"15","author":"Rini","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2023050815233812000_CIT0020","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"8-9","key":"2023050815233812000_CIT0021","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/0959-8049(92)90510-9","article-title":"Can Karnofsky performance status be transformed to the Eastern Cooperative Oncology Group scoring scale and vice versa?","volume":"28A","author":"Verger","year":"1992","journal-title":"Eur J Cancer"},{"issue":"6","key":"2023050815233812000_CIT0022","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s10637-008-9147-y","article-title":"Optimal modeling for phase I design of a two drug combination-results of a phase I study of cisplatin with 9-nitrocamptothecin","volume":"26","author":"Lee","year":"2008","journal-title":"Invest New Drugs"},{"key":"2023050815233812000_CIT0023","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1200\/JGO.19.00111","article-title":"Efficacy and prognostic factors of sunitinib as first-line therapy for patients with metastatic renal cell carcinoma in an arab population","volume":"6","author":"Badran","year":"2020","journal-title":"JCO Glob Oncol"},{"issue":"6","key":"2023050815233812000_CIT0024","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/sim.721","article-title":"Sample size tables for exact single-stage phase II designs","volume":"20","author":"A\u2019Hern","year":"2001","journal-title":"Stat Med"},{"issue":"12","key":"2023050815233812000_CIT0025","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N Engl J Med."},{"issue":"43","key":"2023050815233812000_CIT0026","doi-asserted-by":"crossref","first-page":"17069","DOI":"10.1073\/pnas.0708148104","article-title":"Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy","volume":"104","author":"Ebos","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"issue":"14","key":"2023050815233812000_CIT0027","doi-asserted-by":"crossref","first-page":"3961","DOI":"10.1158\/1078-0432.CCR-12-0002","article-title":"Rapid angiogenesis onset after discontinuation of sunitinib treatment of renal cell carcinoma patients","volume":"18","author":"Griffioen","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"11","key":"2023050815233812000_CIT0028","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1093\/annonc\/mdv357","article-title":"Randomized phase II trial of sunitinib four weeks on and two weeks off versus two weeks on and one week off in metastatic clear-cell type renal cell carcinoma: RESTORE trial","volume":"26","author":"Lee","year":"2015","journal-title":"Ann Oncol"},{"issue":"12","key":"2023050815233812000_CIT0029","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1200\/JCO.2011.36.4133","article-title":"Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma","volume":"30","author":"Motzer","year":"2012","journal-title":"J Clin Oncol"},{"key":"2023050815233812000_CIT0030","doi-asserted-by":"crossref","first-page":"541.e7","DOI":"10.1016\/j.urolonc.2017.05.007","article-title":"Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer.","volume":"35","author":"Iacovelli","year":"2017","journal-title":"Urol Oncol"},{"issue":"11","key":"2023050815233812000_CIT0031","doi-asserted-by":"crossref","first-page":"6413","DOI":"10.21873\/anticanres.13002","article-title":"Sunitinib treatment modification in first-line metastatic renal cell carcinoma: analysis of the STAR-TOR registry","volume":"38","author":"Boegemann","year":"2018","journal-title":"Anticancer Res"},{"issue":"5","key":"2023050815233812000_CIT0032","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1803675","article-title":"Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma","volume":"379","author":"M\u00e9jean","year":"2018","journal-title":"N Engl J Med"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/5\/e254\/50247614\/oyac261.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/5\/e254\/50247614\/oyac261.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T15:45:57Z","timestamp":1683560757000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/28\/5\/e254\/6989644"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,17]]},"references-count":32,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,1,17]]},"published-print":{"date-parts":[[2023,5,8]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyac261","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,5,1]]},"published":{"date-parts":[[2023,1,17]]}}}